Therapeutic strategies in patients with chronic stable coronary artery disease

Cardiovascular Therapeutics

Volumn 29, Issue 6, 2011, Pages

  Zellweger, Michael J ^a   Pfisterer, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chronic coronary artery disease; Medical therapy; Revascularization; Review

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NICORANDIL; NITRATE;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CHRONIC DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DISEASE SEVERITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS;

ANGINA PECTORIS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 82355169175     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00164.x     Document Type: Review

References (70)

1. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: A meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48:1319-1325.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-1660.
4. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 2009;119:1330-1352.
5. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636.
6. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-2515.
7. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516.
8. Pfisterer ME, Zellweger MJ. Therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;361:1407; author reply 1409-1410.
9. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381.
10. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
11. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
12. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992;327:175-181.
13. Smith SC, Jr, Feldman TE, Hirshfeld JW, Jr, et al. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
14. Casterella PJ, Tcheng JE. Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: Practical implications, new clinical data, and recommended guideline revisions. Am Heart J 2008;155:781-790.
15. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-1208.
16. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-1687.
17. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607-1621.
18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
20. Briel M, Nordmann AJ, Bucher HC. Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: Update on recent trials and metaanalyses. Curr Opin Lipidol 2005;16:601-605.
21. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
22. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: A network meta-analysis involving more than 65, 000 patients. J Am Coll Cardiol 2008;52:1769-1781.
23. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-Are they clinically relevant? Eur Heart J 2003;24:225-248.
24. Joy TR, Hegele RA. Narrative review: Statin-related myopathy. Ann Intern Med 2009;150:858-868.
25. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: Comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009;151:622-630.
26. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-76.
27. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: Targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 2007;28:664-672.
28. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318:1730-1737.
29. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550-560.
30. Opie L. Anti-ischemic properties of calcium-channel blockers: Lessons from cardiac surgery. J Am Coll Cardiol 2003;41:1506-1509.
31. Lewin HC, Berman DS. Achieving sustained improvement in myocardial perfusion: Role of isosorbide mononitrate. Am J Cardiol 1997;79:31-35.
32. Rutherford JD. Nitrate tolerance in angina therapy. How to avoid it. Drugs 1995;49:196-199.
33. Abdulla J, Barlera S, Latini R, et al. A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007;9:129-135.
34. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: A systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2006;47:1576-1583.
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
36. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
37. Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998;19(Suppl J):J52-J55.
38. Effect of nicorandil on coronary events in patients with stable angina: The Impact of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-1275.
39. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
40. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536.
41. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
42. Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: A randomized trial. Circulation 2004;109:1371-1378.
43. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682-692.
44. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001:CD001800.
45. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: One-year results of the randomized TIME trial. JAMA 2003;289:1117-1123.
46. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: One-year results. J Am Coll Cardiol 2004;43:1743-1751.
47. Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial. JAMA 2007;297:1985-1991.
48. Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Quality of life after coronary angioplasty or continued medical treatment for angina: Three-year follow-up in the RITA-2 trial. Randomized Intervention Treatment of Angina. J Am Coll Cardiol 2000;35:907-914.
49. O'Rourke RA. Optimal medical therapy is a proven option for chronic stable angina. J Am Coll Cardiol 2008;52:905-907.
50. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): A randomised trial. Lancet 2001;358:951-957.
51. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008;359:677-687.
52. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-1170.
53. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997;350:461-468.
54. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-918.
55. Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: Four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). Circulation 2004;110:1213-1218.
56. Schomig A, Mehilli J, de Waha A, Seyfarth M, Pache J, Kastrati A. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:894-904.
57. Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus with Stable Ischemic Heart Disease. Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction. Circulation 2009;120:2529-2540.
58. Weintraub WS, Barnett P, Chen S, et al. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline driven drug Evaluation (COURAGE) trial. Am Heart J 2006;151:1180-1185.
59. Hlatky MA, Boothroyd DB, Melsop KA, et al. Economic outcomes of treatment strategies for Type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial. Circulation 2009;120:2550-2558.
60. Claude J, Schindler C, Kuster GM, et al. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 2004;25:2195-2203.
61. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350-1358.
62. Kuster GM, Buser P, Osswald S, et al. Comparison of presentation, perception, and six-month outcome between women and men > or = 75 years of age with angina pectoris. Am J Cardiol 2003;91:436-439.
63. Fox KA. COURAGE to change practice? Revascularisation in patients with stable coronary artery disease. Heart 2009;95:689-692.
64. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900-2907.
65. Zellweger MJ, Hachamovitch R, Kang X, et al. Threshold, incidence, and predictors of prognostically high-risk silent ischemia in asymptomatic patients without prior diagnosis of coronary artery disease. J Nucl Cardiol 2009;16:193-200.
66. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-1291.
67. Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: Results from the multicenter registry of 4, 728 patients. J Nucl Med 2003;44:134-139.
68. Jeger RV, Zellweger MJ, Kaiser C, et al. Prognostic value of stress testing in patients over 75 years of age with chronic angina. Chest 2004;125:1124-1131.
69. Simoons ML, Windecker S. Chronic stable coronary artery disease: Drugs vs. revascularization. Eur Heart J 2010;31:530-541.
70. Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 2010;375:763-772.